Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Brent Neuschwander-Tetri MD

Brent A. Neuschwander-Tetri MD

Professor of Internal Medicine and Associate Chair for Clinical Research, Saint Louis University, St. Louis, Missouri

Brent Neuschwander-Tetri, MD, Professor of Internal Medicine and Associate Chair for Clinical Research at Saint Louis University, completed his undergraduate studies at the University of Oregon and he received his M.D. degree from Yale University. He completed his internship and residency in internal medicine at the University of Wisconsin Madison and his fellowship in gastroenterology and hepatology at the University of California San Francisco, working in the UCSF Liver Center Laboratory. In 1991 he joined Bruce Bacon and the faculty at Saint Louis University in the Division of Gastroenterology and Hepatology. He is actively involved in clinical care of patients with liver disease, laboratory research and clinical trials. His laboratory work demonstrated severe NASH in mice fed trans-fats and he continues to explore mechanisms of lipotoxic liver injury and fibrogenesis. He is a member of the NIH-supported NASH Clinical Research Network, the group that conducted the PIVENS and FLINT treatment trials for NASH, and he is a steering committee member of the international TARGET NASH consortium. He speaks nationally and internationally to academic and industry groups on the molecular pathogenesis of NASH and targets of therapy that address substrate-overload lipotoxic liver injury.


Dr. Neuschwander-Tetri has no relevant disclosures.